New onset diabetes during antihypertensive therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review with expert commentary and no systematic search methodology
PubMed 18437139 · doi:10.1038/ajh.2008.17
What was done
Narrative review examining the cardiovascular disease (CVD) implications and clinical management of new-onset diabetes (NOD) arising during antihypertensive treatment, particularly with thiazide-like diuretics and beta-blockers compared to renin-angiotensin system blockers and calcium channel blockers.
What was found
The abstract reports no numerical data, hazard ratios, or statistical results. It notes qualitatively that thiazide-like diuretics and beta-blockers are more likely to provoke hyperglycemia than renin-angiotensin system blockers or calcium channel blockers. However, NOD occurring during diuretic therapy has not been shown to increase CVD in clinical trials or observational studies. Recommended management strategies include potassium correction, combining diuretics with ACE inhibitors or ARBs, or adding hypoglycemic therapy if the diuretic remains essential for blood pressure control.
Why it matters
It highlights that blood pressure reduction remains the primary goal to prevent cardiovascular events, and concerns regarding diuretic-induced hyperglycemia should not deter effective antihypertensive treatment.
Limits
This is a narrative review without systematic search protocols, meta-analytic pooling, or formal study quality appraisal. No quantitative effect sizes, patient counts, or follow-up durations are provided in the abstract.
Cited by
- supports Thiazide diuretics cause hypokalemia, and potassium depletion is the mechanism that raises the risk of developing diabetes.